Tags

Type your tag names separated by a space and hit enter

Safety profile of hydroxyurea in the treatment of patients with Philadelphia-negative chronic myeloproliferative disorders.
Haematologica. 2005 Feb; 90(2):261-2.H

Abstract

The efficacy of hydroxyurea (HU) in myeloproliferative disorders is well documented. HU controls thrombocytosis both in polycythemia vera (PV) and in essential thrombocythemia (ET), while reducing the risk of thrombosis.1 Despite many anectodal reports, no evaluation of the prevalence and type of side effects of HU exists in large series of patients.

Authors

Randi ML
No affiliation info available
Ruzzon E
No affiliation info available
Luzzatto G
No affiliation info available
Tezza F
No affiliation info available
Girolami A
No affiliation info available
Fabris F
No affiliation info available

MeSH

AdultAgedAged, 80 and overBusulfanEnzyme InhibitorsFemaleHumansHydroxyureaLeukemia, Myeloid, Chronic, Atypical, BCR-ABL NegativeMaleMiddle AgedMyeloproliferative DisordersPolycythemia VeraRetrospective StudiesThrombocytosisTime FactorsTreatment Outcome

Pub Type(s)

Letter

Language

eng

PubMed ID

15710584

Citation

Randi, Maria Luigia, et al. "Safety Profile of Hydroxyurea in the Treatment of Patients With Philadelphia-negative Chronic Myeloproliferative Disorders." Haematologica, vol. 90, no. 2, 2005, pp. 261-2.
Randi ML, Ruzzon E, Luzzatto G, et al. Safety profile of hydroxyurea in the treatment of patients with Philadelphia-negative chronic myeloproliferative disorders. Haematologica. 2005;90(2):261-2.
Randi, M. L., Ruzzon, E., Luzzatto, G., Tezza, F., Girolami, A., & Fabris, F. (2005). Safety profile of hydroxyurea in the treatment of patients with Philadelphia-negative chronic myeloproliferative disorders. Haematologica, 90(2), 261-2.
Randi ML, et al. Safety Profile of Hydroxyurea in the Treatment of Patients With Philadelphia-negative Chronic Myeloproliferative Disorders. Haematologica. 2005;90(2):261-2. PubMed PMID: 15710584.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Safety profile of hydroxyurea in the treatment of patients with Philadelphia-negative chronic myeloproliferative disorders. AU - Randi,Maria Luigia, AU - Ruzzon,Elisabetta, AU - Luzzatto,Guido, AU - Tezza,Fabiana, AU - Girolami,Antonio, AU - Fabris,Fabrizio, PY - 2005/2/16/pubmed PY - 2006/8/10/medline PY - 2005/2/16/entrez SP - 261 EP - 2 JF - Haematologica JO - Haematologica VL - 90 IS - 2 N2 - The efficacy of hydroxyurea (HU) in myeloproliferative disorders is well documented. HU controls thrombocytosis both in polycythemia vera (PV) and in essential thrombocythemia (ET), while reducing the risk of thrombosis.1 Despite many anectodal reports, no evaluation of the prevalence and type of side effects of HU exists in large series of patients. SN - 1592-8721 UR - https://www.unboundmedicine.com/medline/citation/15710584/Safety_profile_of_hydroxyurea_in_the_treatment_of_patients_with_Philadelphia_negative_chronic_myeloproliferative_disorders_ DB - PRIME DP - Unbound Medicine ER -